<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03658330</url>
  </required_header>
  <id_info>
    <org_study_id>GY0004</org_study_id>
    <nct_id>NCT03658330</nct_id>
  </id_info>
  <brief_title>Naltrexone Plus Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder</brief_title>
  <official_title>Naltrexone Plus Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Connecticut Healthcare System</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Connecticut Healthcare System</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate if naltrexone plus ketamine is effective in reducing depression and alcohol
      consumption.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary goal of this proposal is to test naltrexone plus repeated ketamine treatment for
      major depressive disorder and alcohol use disorder in an open-label trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2016</start_date>
  <completion_date type="Actual">June 2018</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response in symptoms of depression as measured by the Montgomery-Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>Day 21</time_frame>
    <description>Response is defined as a ≥ 50% improvement from baseline in MADRS scores. The MADRS has a total range of 0-60. Higher scores represent a worse outcome (i.e., more depression).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Obsessive Compulsive Drinking Scale (OCDS)</measure>
    <time_frame>Day 21</time_frame>
    <description>The Obsessive Compulsive Drinking Scale is designed to assess alcohol craving and consumption. The scale has a total score range of 0-56. Higher scores represent a worse outcome (i.e., more alcohol problems).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Major Depressive Disorder</condition>
  <condition>Alcohol Use Disorder</condition>
  <arm_group>
    <arm_group_label>Ketamine + Naltrexone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive (1) intravenous ketamine (0.5 mg/kg) once a week for 4 weeks (a total of 4 infusions) and (2) intramuscular naltrexone (380 mg) once a month (a total of 1 injection).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine + Naltrexone</intervention_name>
    <description>Subjects will receive (1) intravenous ketamine (0.5 mg/kg) once a week for 4 weeks (a total of 4 infusions) and (2) intramuscular naltrexone (380 mg) once a month (a total of 1 injection).</description>
    <arm_group_label>Ketamine + Naltrexone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, 21-65 years old

          2. Current major depressive disorder without psychotic features by DSM-5

          3. Montgomery-Åsberg Depression Rating Scale (MADRS) ≥ 20

          4. Current alcohol use disorder by DSM-5

          5. Heavy drinking at least 3 times in the past month ('heavy drinking' defined as ≥ 5
             standard drinks per day for men and ≥ 4 standard drinks per day for women)

          6. Abstinence from alcohol drinking for &gt; 5 days prior to ketamine infusion

          7. Able to provide written informed consent

        Exclusion Criteria:

          1. Current substance use disorder by DSM-5 in the past 3 months (except alcohol, tobacco,
             or cannabis)

          2. Current or past history of psychotic features or psychotic disorder

          3. Current or past history of delirium or dementia

          4. Current uncontrolled hypertension (systolic BP &gt; 170 mm Hg or diastolic BP &gt; 100 mm
             Hg)

          5. Unstable medical condition or allergy to ketamine, naltrexone, or
             lorazepam---clinically determined by a physician

          6. Imminent suicidal or homicidal risk

          7. Pregnant or nursing women, positive pregnancy test, or inadequate birth control
             methods in women of childbearing potential

          8. Positive opioid or illicit drug screen test (except marijuana)

          9. Opioid use within 10 days prior to study medication (injectable naltrexone) or risks
             for opioid use during the study

         10. Liver enzymes that are three times higher than the upper limit of normal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gihyun Yoon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Connecticut Healthcare System</affiliation>
  </overall_official>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 1, 2018</study_first_submitted>
  <study_first_submitted_qc>September 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2018</study_first_posted>
  <last_update_submitted>September 5, 2018</last_update_submitted>
  <last_update_submitted_qc>September 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VA Connecticut Healthcare System</investigator_affiliation>
    <investigator_full_name>Gihyun Yoon</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Ketamine</keyword>
  <keyword>Naltrexone</keyword>
  <keyword>Depression</keyword>
  <keyword>Alcohol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Alcohol Drinking</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

